Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume.Q2 2026 EPS increased by 26% to $7.94 on a reported basis and increased by 33% … [+37810 chars]Read More
Lilly reports secondquarter 2026 financial results raises fullyear guidance and highlights continued growth and pipeline progress Eli Lilly and Company
